Jones Soda Co. JSDA Company Overview  Stock Message Board

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
Jones Soda Co. JSDA Company Overview 

Stock Message Board http://investorshangout.com/search?q=JSDA&...mp;yt1=Go!

Jones Soda Co. JSDA Current Price and Quotes
Last Price 0.66
Previous Close 0.672 Open 0.68
Daily Range 0.70 - 0.65 52wk Range 0.91 - 0.2315
Volume 156,347 Dividend N/A
Average Vol (3m) 173,885 Yield N/A
Jones Soda Co. JSDA
Company Information

1000 First Avenue South
Suite 100
Seattle, WA 98134
Australia

Website: http://www.jonessoda.com
Phone: 206-624-3357
Email: info@jonessoda.com

Jones Soda Co. JSDA
Headquartered in Seattle, Washington, Jones Soda Co. (OTCQB: JSDA) markets and distributes premium beverages under the Jones Soda and WhoopAss Energy Drink brands and sells through its distribution network in markets primarily across North America. A leader in the premium soda category, Jones is known for its variety of flavors, highest quality ingredients, including pure cane sugar and innovative labeling technique that incorporates always--changing photos sent in from its consumers. Jones Sod...



Jones Soda Co. JSDA
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Not Available
Latest Report Jun 30, 2013 10-Q
CIK 0001083522
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 2080 - Beverages
Incorporated In: WA, USA
Year of Inc. Not Available
Employees 40 a/o Mar 30, 2012
Company Officers/Contacts

Jennifer Cue CEO
Carrie Traner VP, Fin.
Company Directors

Not Available
Company Notes

Note=8-00 State of Incorporation Wyoming changed to Washington concurrent with name change
Formerly=Urban Juice & Soda Co., Ltd. until 8-00
Service Providers

Auditor/Accountant
Peterson Sullivan PLLC
601 Union St.
Suite 2300
Seattle, WA, 98101
United States

Legal Counsel
Cairncross & Hempelmann
524 Second Avenue
Seattle, WA, 98104-2323
United States

Investor Relations Firm
Not Available

Jones Soda Co. JSDA
JSDA Security Details

Share Structure

Market Value1 $25,529,075 a/o Sep 13, 2013
Shares Outstanding 38,680,416 a/o Aug 06, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Dec 31, 2011
Par Value  No Par Value
Shareholders

Shareholders of Record 277 a/o Mar 27, 2013
Security Notes

Note = Company delisted from NASDAQ on 09/20/12
Short Selling Data

Short Interest 472,474 (8.85%)
Aug 30, 2013
Significant Failures to Deliver  No
Transfer Agent(s)

Computershare Trust Company, N.A

Jones Soda Co. JSDA Recent News

Sept 4, 2013 Jones Soda Unveils Limited Edition Halloween Cans
Sept 2, 2013 OTC Daily Alert Stock Watch - Jones Soda Co., (OTC: JSDA)
Aug 19, 2013 Hangover Joe's Hires New Executive VP to Spearhead Growth Plan
Aug 13, 2013 Jones Soda Launches "Made in Michigan"
Aug 9, 2013 Jones Soda Co. Reports Fiscal 2013 Second Quarter Results
Jul 30, 2013 Jones Soda Announces Second Quarter Fiscal 2013 Earnings Conference Call
Jul 11, 2013 PENNYSTOCKBLING Daily Stock Watch Primo Water Corporation (NASDAQ RMW), Jones Soda Co. (NASDAQ:JSDA), and EQ Labs, Inc. (OTC:EQLB)


Jones Soda Co. JSDA Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 16,384 17,425 17,557 26,013
Cost of Revenue 11,902 13,120 13,484 22,123
Gross Profit 4,482 4,305 4,073 3,890
Operating Expenses

Research and Development - - - -
Sales, General and Admin. 7,279 11,531 10,659 14,416
Non-Recurring Items - - - -
Other - - - -
Operating Income (2,797) (7,226) (6,586) (10,445)
Income From Continuing Operations

Add'l Income/Expense Items (15) 104 142 (30)
Earnings Before Interest and Tax (2,812) (7,122) (6,444) (10,475)
Interest Expense - - - -
Earnings Before Tax (2,812) (7,122) (6,444) (10,475)
Income Tax 91 32 (338) 72
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (2,903) (7,154) (6,106) (10,547)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (2,903) (7,154) (6,106) (10,547)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (2,903) (7,154) (6,106) (10,547)

JSDA Jones Soda Co. Research DD Guide

JSDA Jones Soda Co. Stock Message Board http://investorshangout.com/search?q=JSDA&...mp;yt0=Go!
JSDA Jones Soda Co. Stock Quote http://www.otcmarkets.com/stock/JSDA/quote
JSDA Jones Soda Co. Stock Chart http://www.otcmarkets.com/stock/JSDA/chart
JSDA Jones Soda Co. Company Info http://www.otcmarkets.com/stock/JSDA/company-info
JSDA Jones Soda Co. Recent News http://www.otcmarkets.com/stock/JSDA/news
JSDA Jones Soda Co. Financials http://www.otcmarkets.com/stock/JSDA/financials
JSDA Jones Soda Co. Filings and Disclosure http://www.otcmarkets.com/stock/JSDA/filings
JSDA Jones Soda Co. Short Sales http://www.otcmarkets.com/stock/JSDA/short-sales
JSDA Jones Soda Co. Insider Disclosure http://www.otcmarkets.com/stock/JSDA/insider-transactions
JSDA Jones Soda Co. Research Reports http://www.otcmarkets.com/stock/JSDA/research
JSDA Jones Soda Co. Summary http://finance.yahoo.com/q?s=JSDA
JSDA Jones Soda Co. Historical Prices http://finance.yahoo.com/q/hp?s=JSDA+Historical+Prices
JSDA Jones Soda Co. Interactive Chart http://finance.yahoo.com/echarts?s=JSDA
JSDA Jones Soda Co. Basic Chart http://finance.yahoo.com/q/bc?s=JSDA+Basic+Chart
JSDA Jones Soda Co. Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=JSDA+Basic+Tech.+Analysis
JSDA Jones Soda Co. Headlines http://finance.yahoo.com/q/h?s=JSDA+Headlines
JSDA Jones Soda Co. Press Releases http://finance.yahoo.com/q/p?s=JSDA+Press+Releases
JSDA Jones Soda Co. Company Profile http://finance.yahoo.com/q/pr?s=JSDA+Profile
JSDA Jones Soda Co. Key Statistics http://finance.yahoo.com/q/ks?s=JSDA+Key+Statistics
JSDA Jones Soda Co. Industry http://finance.yahoo.com/q/in?s=JSDA+Industry
JSDA Jones Soda Co. Major Holders http://finance.yahoo.com/q/mh?s=JSDA+Major+Holders
JSDA Jones Soda Co. Insider Transactions http://finance.yahoo.com/q/it?s=JSDA+Insider+Transactions
JSDA Jones Soda Co. Insider Roster http://finance.yahoo.com/q/ir?s=JSDA+Insider+Roster
JSDA Jones Soda Co. Income Statement http://finance.yahoo.com/q/is?s=JSDA
JSDA Jones Soda Co. Balance Sheet http://finance.yahoo.com/q/bs?s=JSDA
JSDA Jones Soda Co. Cash Flow http://finance.yahoo.com/q/cf?s=JSDA+Cash+Flow&annual
JSDA Jones Soda Co. Nasdaq http://www.nasdaq.com/symbol/JSDA
JSDA Jones Soda Co. Market Watch http://www.marketwatch.com/investing/stock/JSDA
JSDA Jones Soda Co. Bloomberg http://www.bloomberg.com/quote/JSDA:US
JSDA Jones Soda Co. Morningstar http://quotes.morningstar.com/stock/s?t=JSDA
JSDA Jones Soda Co. Bussinessweek http://investing.businessweek.com/research/st...icker=JSDA
JSDA Jones Soda Co. Barchart http://www.barchart.com/quotes/stocks/JSDA
JSDA Jones Soda Co. OTC Short Report http://otcshortreport.com/index.php?index=JSDA
JSDA Jones Soda Co. Investopedia http://www.investopedia.com/markets/stocks/JSDA/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading